Professor, Laboratory Medicine and Epidemiology/Biostatistics, UCSF
| CONTACT | |
|
murphy@ucsf.edu Blood Centers of the Pacific, 270 Masonic Avenue, San Francisco, CA 94118 |
| EDUCATION | |
|
Massachusetts Institute of Technology, B.S., 1974, Marine Biology
|
|
| PROFESSIONAL EXPERIENCE | |
|
1974-1976 |
Research in human deep-sea diving physiology, COMEX Diving Company, Marseille,France. |
|
1981-1984 |
Resident in Internal Medicine, Boston University Medical Center, Boston, MA. |
|
1984-1988 |
Medical Staff Fellow, National Cancer Institute, Bethesda, MD. |
|
1986 |
Honorary Lecturer, University Hospital of the West Indies, Kingston, JA. |
|
1988-2001 |
Attending physician, AIDS Clinic, San Francisco General Hospital. |
|
1988-1994 |
Assistant Professor, Departments of Laboratory Medicine, Medicine, and Epidemiology/Biostatistics, University of California, San Francisco, CA. |
|
1994-2000 |
Associate Professor, Departments of Laboratory Medicine, Medicine, and Epidemiology/Biostatistics, University of California, San Francisco, CA. |
|
1995-1996 |
Visiting Researcher, Institut Pasteur, Paris, France. |
|
2000-present |
Professor, Departments of Laboratory Medicine and Epidemiology/Biostatistics, University of California San Francisco |
| HONORS & AWARDS | |
|
1970 |
Westinghouse Scholarship |
|
1980-81 |
University of California Graduate Scholarship |
|
1984 |
Chateaubriand prize of the French Government |
|
1984 |
International Agency for Cancer Research Fellowship (declined) |
|
1988 |
FDA Commissioners Special Citation |
|
1989-92 |
Charles E. Culpeper Scholarship |
|
1995-96 |
Fulbright Scholarship, France |
|
1995-96 |
NIH Fogarty Senior International Fellowship |
|
2003 |
President, International Retrovirology Association |
| SELECTED PUBLICATIONS | |
|
(selected from a total of 113) | |
|
Murphy EL, Hanchard B, Figueroa JP, Gibbs WN, Goedert JJ, and Blattner WA. Modelling the risk of adult T-cell leukemia/lymphoma in persons infected with human T-lymphotropic virus type I. Int J Cancer 1989; 43:250-3. | |
|
Murphy EL, Figueroa JP, Gibbs WN, Brathwaite A, Holding-Cobham M, Cranston B, Hanchard B, and Blattner WA. Sexual transmission of human T-lymphotropic virus type I. Ann Intern Med 1989; 111(7):555-60. | |
|
Murphy EL, Figueroa JP, Gibbs WN, et al. Human T-lymphotropic virus type I (HTLV-I) seroprevalence in Jamaica: I. Demographic determinants. Am J Epidemiol 1991; 133(11):1114-24. | |
|
Feigal E, Murphy EL, Vranizan K, et al. HTLV-I/II in intravenous drug users in San Francisco: Risk factors associated with seropositivity. J Infect Dis 1991;164:36-42. | |
|
Busch MP, Eble BE, Khayam-Bashi H, Murphy EL, Heilbron D, Kwok S, Sninsky J, Perkins HA, Vyas GN. Evaluation of contemporary screened blood donors for HIV-I infection. N Engl J Med 1991; 325:1-5. | |
|
Murphy EL. HTLV-II-related disease. Lancet 1993; 341:888.Kramer A, Maloney EM, Morgan OSC, Rodgers-Johnson P, Manns A, Murphy EL, Larsen S, Cranston B, Murphy J, Benichou J, Blattner WA. Risk factors and cofactors for HAM/TSP in Jamaica. Am J Epidemiol 1995;142:1212-20. | |
|
Murphy EL, Bryzman S, Williams AE, et al. Demographic determinants of hepatitis C virus (HCV) seroprevalence among blood donors in the United States. JAMA 1996; 275:995-1000. | |
|
Murphy EL, Fridey J, Smith JW, et al. High prevalence of HTLV associated myelopathy in a cohort of HTLV I and HTLV II infected blood donors. Neurology 1997;48:315 20. | |
|
Murphy EL, Glynn SA, Fridey J, et al. Increased prevalence of infectious diseases and other adverse outcomes in HTLV-I and -II infected blood donors. J Infect Dis 1997;176:1468-75. | |
|
Murphy EL, Mahieux R, de The G, et al. Molecular epidemiology of HTLV-II among U.S. blood donors and intravenous drug users: an age-cohort effect for HTLV-II RFLP type a0. Virology 1998;242:425-34. | |
|
Murphy EL, Glynn S, Watanabe K, et al. Laboratory test differences associated with HTLV-I and HTLV-II infection. J Acq Immun Defic Syndr Hum Retroviol 1998;17:332-8. | |
|
Murphy EL, Glynn SA, Fridey J, et al. Increased incidence of infectious diseases and neurologic abnormalities during prospective follow-up of HTLV-II and -I infected blood donors. Arch Intern Med 1999;159:1485-91. | |
|
Murphy EL, Watanabe K, Nass CC, Ownby H, Williams A, Nemo G. Evidence among blood donors for a 30-year old epidemic of HTLV-II infection in the United States. J Infect Dis 1999;180:1777-83. | |
|
Murphy EL, Bryzman SM, Glynn SA, et al. Risk factors for hepatitis C virus infection in United States blood donors. Hepatology 2000;31:756-62. | |
|
Liu H, Leung P, Glynn S, Murphy EL. Human T-lymphotropic virus type II (HTLV-II) RFLP subtypes A0 and B4/B5 are associated with different demographic and geographic characteristics in the United States. Virology 2001;279:90-6. | |
|
Collier AC, Kalish LA, Busch MP, Gernsheimer T, Assmann SF, Lane TA, Asmuth DM, Lederman MM, Murphy EL, Kumar P, Kelley M, Flanigan TP, McMahon DK, Sacks HS, Kennedy MS, Holland PV. Leukocyte-reduced red blood cell transfusions in patients with anemia and human immunodeficiency virus infection. The VAT Study: a randomized controlled trial. JAMA 2001;285:1592-1601. | |
|
Murphy EL, Collier AC, Kalish LA, Assmann SF, Para MF, Flanigan TP, Kumar PN, Mintz L, Wallach FR, Nemo GJ. Highly active antiretroviral therapy (HAART) decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med 2001;135:17-26. | |
|
Murphy EL, Wu Y, Ownby HE, et al. Delayed hypersensitivity skin testing to mumps and candida albicans antigens is normal in middle-aged HTLV-I and -II-infected U.S. cohorts. AIDS Res Hum Retroviruses 2001;17:1273-7. | |
|
Schreiber GB, Glynn SA, Damesyn MA, Wright DJ, Tu Y, Dodd RY, Murphy EL. Lapsed donors: an untapped resource. Transfusion 2003;43:17-24. | |
|
Glynn SA, Busch MP, Schreiber GB, Murphy EL, Wright DJ, Tu Y, Kleinman SH. Effect of a national disaster on blood supply and safety. JAMA 2003;289:2246-53. | |
|
Murphy EL, Grant RM, Kropp J, Oliveira A, Lee TH, Busch MP. Increased human T-lymphotropic virus type II proviral load following highly active retroviral therapy in HIV-coinfected patients. J Acquir Immune Defic Syndr 2003;33:655-6. | |
|
Orland JR, Engstrom J, Fridey J, Sacher RA, Smith JW, Nass C, Garratty G, Newman B, Smith D, Wang B, Loughlin K, Murphy EL. Prevalence and clinical features of HTLV neurologic disease in the HTLV Outcomes Study. Neurology 2003;61:1588-94. | |
|
Murphy EL, Wang B, Sacher RA, Fridey J, Smith J, Nass C, Newman B, Ownby H, Garratty G, Hutching S, Schreiber GB. Respiratory and urinary tract infections, arthritis, and asthma associated with HTLV-II and HTLV-I infection. Emerg Infect Dis 2004;10:109-116. | |
|
Orland JR, Wang B, Wright DJ, Nass CC, Garratty G, Smith JW, Newman B, Smith DM, Murphy EL. Increased mortality associated with HTLV-II infection in blood donors: a prospective cohort study. Retrovirology 2004;1:4. | |
|
Murphy EL, Lee TH, Chafets D, Nass CC, Wang B, Loughlin K, Smith D. Higher HTLV proviral is associated with HTLV-I vs. HTLV-II, HTLV-II subtype A versus B, and with male sex and a history of blood transfusion. J Infect Dis 2004;190:504-10. | |
|
Jarvis G, Janoff EN, Cheng H, DeVita D, Fasching C, McCulloch CE, Murphy EL. Human T lymphotropic virus type II infection and humoral responses to pneumococcal polysaccharide and tetanus toxoid vaccines. J Infect Dis 2005:191:1239-44. | |
|
Roucoux DH, Wang B, Smith D, Nass CC, Smith J, Hutching ST, Newman B, Lee T-H, Chafets D, Murphy EL. A prospective study of sexual transmission of human T-lymphotropic virus (HTLV-I and HTLV-II). J Infect Dis 2005;191:1490-7. | |
|
Proietti FA, Carneiro-Proietti ABF, Catalan-Soares BC, Murphy EL. Global epidemiology of HTLV-I infection and associated diseases. Oncogene 2005;24:6058-68. | |
|
Murphy EL, Jacobson S, Franchini G, Taylor GP, Hanchard B, Morgan O, Lairmore M. International Retrovirology Association brings together scientists and clinicians to bridge discoveries about human T-lymphotropic viruses from the laboratory to clinical trials. Retrovirology 2005;2(1):22. | |
|
Gabet AS, Moules V, Sibon D, Nass CC, Mortreux F, Mauclere P, Gessain A, Murphy EL, Wattel E. Endemic versus epidemic viral spreads display distinct patterns of HTLV-2b replication. Virology 2006;345:13-21. | |
|
Busch MP, Glynn SA, Stramer SL, Orland J, Murphy EL, Wright DJ, Kleinman S. Correlates of hepatitis C virus (HCV) RNA negativity among HCV seropositive blood donors. Transfusion 2006;46:469-75. | |
|
Goncalez TT, Sabino EC, Murphy EL, Chen S, Chamone DAF, McFarland W. HIV test-seeking motivation in blood donors, Sao Paulo, Brazil. Vox Sang 2006;90:170-6. | |
|
Barcellos NT, Murphy EL, Fuchs SC. HTLV I/II infection: prevalence and risk factors in individuals testing for HIV in counseling centers from southern Brazil. Sex Trans Dis 2006;33:302-6. | |
|
Carneiro-Proietti ABF, Catalan-Soares BC, Castro-Costa CM, Murphy EL, Sabino EC, Hisada M, Galvao-Castro B, Alcantara LCJ, Remondegui C, Verdonck K, Proietti FA. HTLV in the Americas: challenges and perspectives. Rev Panam Salud Publica 2006;19:44-53. | |
|
Glynn SA, Schreiber GB, Murphy EL, Kessler D, Higgins M, Wright D, Mathew S, Tu S, King M, Smith JW. Factors influencing the decision to donate: a racial/ethnic comparison. Transfusion 2006;46:9. | |
|
Reich P, Roberts P, Laabs N, Chinn A, McEvoy P, Hirschler N, Murphy EL. A randomized trial of blood donor recruitment strategies. Transfusion 2006;46:1090-96. |
|
|
12/8/06 |
|
